Empagliflozin, another SGLT2-inhibitor, reduces hepatic fat content and significantly improves steatosis and liver fibrosis, as well as reduces AST and ALT in MAFLD patients with or without the condition of T2DM [97–99]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.